Subsidiary Board Appointment

Stanelco PLC
11 March 2002



                                    STANELCO PLC



                          Subsidiary Board Appointment



Stanelco, the Rf (Radio frequency) applications group, announces the
non-executive  appointment of Dr Richard Yarwood, 47, Regional President,
Europe, of R P Scherer Corporation, to the Board of its subsidiary, InGel
Technologies Limited, which it recently established to commercialise its
technology for the manufacture of liquid-filled capsules without using gelatine.



R P Scherer, a subsidiary of Cardinal Health, a Fortune 100 company, is one of
the world's premier drug delivery companies and has the leading global position
in softgel capsule technology. In December 2001, R P Scherer signed a licence
agreement with InGel, agreed to acquire 10% of InGel, and acquired 3% of the
share capital of Stanelco.



Richard Yarwood is a qualified pharmacist and led the successful development and
commercial launch of Zydis, R.P Scherer's fast dissolving dose form system.
Previously, Richard held positions with Wyeth Research, Pfizer, Merck and
Wellcome.



Richard Yarwood joins another senior executive of R P Scherer, Tom Stuart, who
has recently become Regional President, Americas, on the Board of InGel.






Enquiries:

Stanelco PLC                                                      01489-570 991
 Ian Balchin (CEO)

Bankside Consultants Limited
 Charles Ponsonby                                                 020-7444 4166





                      This information is provided by RNS
            The company news service from the London Stock Exchange